MCID: GND003
MIFTS: 46

Gonadal Disease

Categories: Endocrine diseases

Aliases & Classifications for Gonadal Disease

MalaCards integrated aliases for Gonadal Disease:

Name: Gonadal Disease 12 15
Gonadal Disorders 44 73
Gonadal Dysfunction 55

Classifications:



External Ids:

Disease Ontology 12 DOID:2277
MeSH 44 D006058
NCIt 50 C26786
UMLS 73 C0018050

Summaries for Gonadal Disease

Disease Ontology : 12 An endocrine system disease that is located in the gonads.

MalaCards based summary : Gonadal Disease, also known as gonadal disorders, is related to pituitary tumors and acromegaly. An important gene associated with Gonadal Disease is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Methyltestosterone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include the gonads, ovary and breast, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Related Diseases for Gonadal Disease

Diseases related to Gonadal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Related Disease Score Top Affiliating Genes
1 pituitary tumors 30.6 GH1 IGF1 POMC
2 acromegaly 30.4 GH1 IGF1 POMC
3 prader-willi syndrome 30.2 GH1 GNRH1 IGF1 POMC
4 pituitary gland disease 30.0 CRH GH1 GNRH1 IGF1 POMC
5 hypopituitarism 30.0 CRH GH1 GNRH1 IGF1 POMC
6 hypogonadism 29.2 ANOS1 GNRH1 GNRHR KISS1 KISS1R NR0B1
7 acidophil adenoma 11.0 IGF1 POMC
8 lymphocytic hypophysitis 10.9 GH1 POMC
9 adenohypophysitis 10.9 GH1 POMC
10 pituitary infarct 10.9 GNRH1 IGF1 POMC
11 chiasmal syndrome 10.9 GNRH1 POMC
12 49, xxxxx 10.9
13 anorchia 10.8 NR5A1 SRY
14 pseudohypoparathyroidism, type ia 10.8 GH1 IGF1
15 adrenal rest tumor 10.8 GNRH1 NR5A1 POMC
16 pituitary apoplexy 10.8 GNRH1 POMC
17 hyperpituitarism 10.8 GH1 IGF1 POMC
18 hypothyroidism, congenital, nongoitrous, 4 10.8 GH1 IGF1 POMC
19 sheehan syndrome 10.8 CRH IGF1 POMC
20 chromophobe adenoma 10.8 GH1 GNRH1 POMC
21 fasting hypoglycemia 10.8 CRH IGF1 POMC
22 pituitary-dependent cushing's disease 10.8 CRH GNRH1 POMC
23 endogenous depression 10.8 CRH GNRH1 POMC
24 persistent fetal circulation syndrome 10.8 CRH IGF1 POMC
25 pituitary adenoma 1, multiple types 10.8 GH1 IGF1
26 endocrine organ benign neoplasm 10.8 CRH IGF1 POMC
27 pituitary hormone deficiency, combined, 2 10.8 GH1 IGF1 POMC
28 47, xxy 10.8 AR SHBG
29 pituitary carcinoma 10.8 CRH POMC
30 adrenal gland hyperfunction 10.7 CRH GH1 POMC
31 pituitary adenoma, prolactin-secreting 10.7 GH1 IGF1 POMC
32 craniopharyngioma 10.7 GH1 GNRH1 IGF1
33 acth deficiency, isolated 10.7 CRH POMC
34 chronic fatigue syndrome 10.7 CRH IGF1 POMC
35 postmenopausal atrophic vaginitis 10.7 AR SHBG
36 withdrawal disorder 10.7 AR CRH POMC
37 androgen insensitivity, partial 10.7 AR SHBG
38 lipoid congenital adrenal hyperplasia 10.7 NR5A1 POMC SRY
39 ovarian hyperstimulation syndrome 10.7 AMH FSHR GNRH1
40 overnutrition 10.7 IGF1 POMC SHBG
41 prostatic adenoma 10.7 AR SHBG
42 acquired metabolic disease 10.6 IGF1 POMC SHBG
43 freemartinism 10.6 AMH GNRH1 SRY
44 hypogonadotropic hypogonadism 23 without anosmia 10.6 FSHR GNRH1 GNRHR
45 mccune-albright syndrome 10.6 AMH GH1 IGF1
46 empty sella syndrome 10.6 GH1 GNRH1 IGF1 POMC
47 nodular prostate 10.6 AR GNRH1
48 hypothalamic disease 10.6 CRH GH1 GNRH1 POMC
49 adrenal cortex disease 10.6 CRH NR0B1 POMC
50 adrenal gland disease 10.6 CRH NR0B1 POMC

Graphical network of the top 20 diseases related to Gonadal Disease:



Diseases related to Gonadal Disease

Symptoms & Phenotypes for Gonadal Disease

MGI Mouse Phenotypes related to Gonadal Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.25 GNRH1 AMH AR GNRHR CRH IGF1
2 homeostasis/metabolism MP:0005376 10.21 AMH GNRH1 AR GNRHR CRH IGF1
3 growth/size/body region MP:0005378 10.18 GNRH1 AR GNRHR CRH IGF1 FSHR
4 integument MP:0010771 10.02 GNRH1 AR GNRHR CRH IGF1 FSHR
5 adipose tissue MP:0005375 10 AR CRH IGF1 FSHR KISS1 KISS1R
6 nervous system MP:0003631 9.9 FSHR GNRH1 AR CRH IGF1 KISS1
7 neoplasm MP:0002006 9.8 AMH GNRH1 AR IGF1 FSHR NR0B1
8 renal/urinary system MP:0005367 9.56 GNRH1 AR GNRHR CRH IGF1 KISS1
9 reproductive system MP:0005389 9.36 GNRH1 AMH AR GNRHR IGF1 FSHR

Drugs & Therapeutics for Gonadal Disease

Drugs for Gonadal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 752)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010
2
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
3
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 315-37-7 9416
4
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5949-44-0
5
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 53714-56-0 3911 657181
6
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
7
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 427-51-0
8
Drospirenone Approved Phase 4,Phase 3,Phase 1,Not Applicable 67392-87-4 68873
9
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
10 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
11
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-63-6 5991
12
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
13
Orlistat Approved, Investigational Phase 4,Phase 2,Not Applicable 96829-58-2 3034010
14
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
15
Ganirelix Approved Phase 4,Phase 2,Early Phase 1,Not Applicable 123246-29-7, 124904-93-4 25081094
16
Dihydrotachysterol Approved Phase 4,Phase 2,Phase 1 67-96-9 5281010 5311071
17
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
18
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 7440-66-6 23994
19
Pioglitazone Approved, Investigational Phase 4,Not Applicable,Early Phase 1 111025-46-8 4829
20
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
21
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
22
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
23
Simvastatin Approved Phase 4,Phase 3,Not Applicable 79902-63-9 54454
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
25
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
26
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
27
Resveratrol Approved, Experimental, Investigational Phase 4,Phase 1,Not Applicable 501-36-0 445154
28
Lenograstim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
29
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
30
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
31
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
32
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 763113-22-0 23725625
33
Dutasteride Approved, Investigational Phase 4,Phase 2,Phase 1 164656-23-9 152945 6918296
34
Buserelin Approved, Investigational Phase 4 57982-77-1
35
Menotropins Approved Phase 4,Phase 1,Phase 2,Not Applicable 61489-71-2, 9002-68-0 5360545
36
Nafarelin Approved Phase 4 76932-56-4 16129618 25077649
37
Liraglutide Approved Phase 4 204656-20-2 44147092
38
Aspirin Approved, Vet_approved Phase 4,Phase 2,Early Phase 1 50-78-2 2244
39
Alogliptin Approved Phase 4 850649-61-5 11450633
40
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 616-91-1 12035
41
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
42
Sevoflurane Approved, Vet_approved Phase 4,Phase 2,Not Applicable 28523-86-6 5206
43
Citalopram Approved Phase 4 59729-33-8 2771
44
Danazol Approved Phase 4 17230-88-5 28417
45
Hydroxocobalamin Approved Phase 4,Not Applicable 13422-51-0 11953898 44475014
46
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
47
Acarbose Approved, Investigational Phase 4,Not Applicable 56180-94-0 441184
48
Tranexamic Acid Approved Phase 4 1197-18-8 5526
49
Norethindrone Approved Phase 4,Phase 2,Not Applicable,Early Phase 1 68-22-4 6230
50
Rosiglitazone Approved, Investigational Phase 4,Not Applicable 122320-73-4 77999

Interventional clinical trials:

(show top 50) (show all 2846)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism Unknown status NCT02310074 Phase 4 Pulsatile Gonadotropin Releasing Hormone;Human chorionic gonadotropin;Urinary Follicle-Stimulating Hormone
2 Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men Unknown status NCT01699178 Phase 4 Oral testosterone undecanoate;Transdermal testosterone gel (AndroGel)
3 Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls Unknown status NCT01278290 Phase 4 Triptorelin acetate and Gonadorelin acetate;Gonadorelin acetate and Triptorelin acetate
4 Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children Unknown status NCT00438217 Phase 4 Triptorelin (GnRH agonists);Leuprolide (GnRH agonists)
5 Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism Unknown status NCT02140515 Phase 4 Lutropin alfa;Follitropin alfa and Lutropin alfa
6 Effect of Androgel on Type 2 Diabetic Males With Hypogonadism Unknown status NCT00350701 Phase 4 androgel;androgel 10g;placebo
7 Administration of Single High Dose Letrozole for Ovulation Induction Unknown status NCT02703649 Phase 4 Letrozole
8 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4 Testosterone
9 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
10 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
11 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
12 The Impact on Ovarian Reserve After Single-port, Two-port, or Four-port Access Laparoscopic Ovarian Cyst Enucleation Unknown status NCT01631253 Phase 4
13 Effects of ADSC Therapy in Women With POF Unknown status NCT01853501 Phase 4
14 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
15 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
16 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
17 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
18 Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation Unknown status NCT01103518 Phase 4 Ethinyl Estradiol + Cyproterone acetate
19 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
20 Testosterone for Peripheral Vascular Disease Unknown status NCT00504712 Phase 4 Testosterone;0.9% saline
21 Metformin in Infertile PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
22 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
23 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
24 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
25 Subcutaneous vs. Intramuscular Testosterone Completed NCT03091348 Phase 4 Testosterone
26 Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
27 Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ Completed NCT02937740 Phase 4 NATESTO Testosterone Nasal Gel
28 Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty Completed NCT02920515 Phase 4 Triptorlin or Leuprorelin;Zhibo dihuang pills;Dabu ying pills
29 The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111473 Phase 4 Testosterone
30 The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel Completed NCT01893281 Phase 4 Topical Testosterone Solution
31 Vitamin D Treatment and Hypogonadism in Men Completed NCT01748370 Phase 4 Vitamin D supplementation in hypogonadal men;Vitamin D supplementation in eugonadal men;Placebo hypogonadal;Placebo eugonadal
32 The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty Completed NCT01634321 Phase 4 Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
33 Effects of Medications in Patients With Hypogonadism Completed NCT01601327 Phase 4 Testosterone enanthate (Sustanon 250 mg);Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU);Testosteron gel (Testojel 50 mg)
34 The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups Completed NCT01454011 Phase 4 Testosteron 250mg injection;Testosterone 50mg transdermal application
35 Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism Completed NCT01107067 Phase 4 Sustanon
36 Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Completed NCT00752869 Phase 4 dutasteride;placebo
37 Effects of Testosterone on Myocardial Repolarization Completed NCT03126656 Phase 4 Testosterone Undecanoate
38 Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) Completed NCT01560546 Phase 4 Testosterone;Placebo
39 Testosterone for Men With Insulin Treated Type 2 Diabetes Completed NCT00349362 Phase 4 Testosterone;0.9% saline
40 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS Completed NCT01815138 Phase 4 hCG;hCG
41 Endometrial Receptivity After GnRH Agonist Triggering Completed NCT01500863 Phase 4 hCG;triptorelin;Triptorelin, estradiol valerate, micronized vaginal progesterone;triptorelin, hCG;triptorelin, hCG;triptorelin, recombinant LH
42 Testosterone Replacement in Men With Diabetes and Obesity Completed NCT01127659 Phase 4 testosterone;placebo
43 Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles Completed NCT00627406 Phase 4 Buserelin and Pregnyl;Pregnyl;Buserelin and Pregnyl;Pregnyl
44 The Use of GnRH Agonist Trigger in the Prevention of OHSS Completed NCT00349258 Phase 4 Leuprolide acetate
45 TRADE-Testosterone Replacement and Dutasteride Effectiveness Completed NCT00194675 Phase 4 Dutasteride;Testosterone gel;Placebo dutasteride
46 Endothelial Dysfunction, Inflammation and Insulin Resistance in Congenital Hypogonadism and Effect of Testosteron Replacement Therapy Completed NCT02171390 Phase 4 Testosterone 250mg injection;Testosteron 50 mg transdermal gel
47 FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST) Completed NCT01969201 Phase 4 Urofollitrophin;Follitrophin alpha
48 The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism Completed NCT01533129 Phase 4 Testogel 50 mg transdermal gel;Testosterone 250mg injection
49 Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility Completed NCT01250821 Phase 4 Menopur
50 Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism Completed NCT01160341 Phase 4 Testosteron

Search NIH Clinical Center for Gonadal Disease

Cochrane evidence based reviews: gonadal disorders

Genetic Tests for Gonadal Disease

Anatomical Context for Gonadal Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Gonadal Disease:

19
The Gonads

MalaCards organs/tissues related to Gonadal Disease:

41
Ovary, Breast, Testes, Bone, Lung, T Cells, Liver

Publications for Gonadal Disease

Articles related to Gonadal Disease:

# Title Authors Year
1
CBX2 gene analysis in patients with 46,XY and 46,XX gonadal disorders of sex development. ( 23219007 )
2013
2
Partial deletion of the NR5A1 (SF1) gene detected by synthetic probe MLPA in a patient with XY gonadal disorder of sex development. ( 21654157 )
2011

Variations for Gonadal Disease

Expression for Gonadal Disease

Search GEO for disease gene expression data for Gonadal Disease.

Pathways for Gonadal Disease

GO Terms for Gonadal Disease

Cellular components related to Gonadal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 AMH ANOS1 CRH GH1 GNRH1 IGF1
2 extracellular space GO:0005615 9.23 AMH ANOS1 CRH GH1 GNRH1 IGF1

Biological processes related to Gonadal Disease according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.95 AMH GH1 GNRH1 IGF1 POMC
2 positive regulation of gene expression GO:0010628 9.89 AMH AR CRH IGF1 NR5A1
3 cell-cell signaling GO:0007267 9.85 AMH AR GNRH1 NR5A1 POMC
4 neuropeptide signaling pathway GO:0007218 9.77 KISS1R POMC PROKR2
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.73 FSHR GH1 IGF1
6 steroid hormone mediated signaling pathway GO:0043401 9.69 AR NR0B1 NR5A1
7 male gonad development GO:0008584 9.67 AR FSHR NR0B1 NR5A1
8 intracellular receptor signaling pathway GO:0030522 9.65 AR NR0B1 NR5A1
9 hypothalamus development GO:0021854 9.59 CRH NR0B1
10 regulation of systemic arterial blood pressure GO:0003073 9.58 AR FSHR
11 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.58 AR FSHR
12 sex differentiation GO:0007548 9.58 AMH AR SRY
13 Leydig cell differentiation GO:0033327 9.57 AR NR0B1
14 positive regulation of male gonad development GO:2000020 9.54 NR5A1 SRY
15 adrenal gland development GO:0030325 9.5 CRH NR0B1 NR5A1
16 gonad development GO:0008406 9.43 AMH FSHR NR0B1
17 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.33 AR GH1 IGF1
18 male sex determination GO:0030238 9.13 GNRH1 NR0B1 SRY
19 sex determination GO:0007530 8.8 AMH NR0B1 NR5A1
20 signal transduction GO:0007165 10.18 AR CRH FSHR GNRH1 GNRHR IGF1
21 G-protein coupled receptor signaling pathway GO:0007186 10.03 CRH FSHR GNRH1 GNRHR KISS1 KISS1R

Molecular functions related to Gonadal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid hormone receptor activity GO:0003707 9.43 AR NR0B1 NR5A1
2 nuclear receptor activity GO:0004879 9.33 AR NR0B1 NR5A1
3 protein-hormone receptor activity GO:0016500 9.32 FSHR GNRHR
4 hormone activity GO:0005179 9.1 AMH CRH GH1 GNRH1 IGF1 POMC
5 androgen binding GO:0005497 8.96 AR SHBG

Sources for Gonadal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....